Anthonius (Ton) de Boer new MEB chairman
Prof. Ton de Boer is to take over as the new chairman of the Medicines Evaluation Board (MEB) as of 1 August 2017. This was announced during the MEB meeting on 1 June 2017. Ton de Boer is a doctor, clinical pharmacologist and epidemiologist. He is professor in Pharmacotherapy at Utrecht University. The Minister for Health, Welfare and Sport has appointed him as successor to the current chairman, Prof. Bert Leufkens, who is stepping down on 1 August.
As MEB secretary and Executive Director, Hugo Hurts, explains, “In Ton de Boer the MEB will have a multitalented chairman who has a broad network within the national medicines chain. Thanks to his scientific expertise he is able to make the link with medicinal use in practice. We expect Ton de Boer to be a worthy successor to Bert Leufkens.”
Ton de Boer adds, “Patients have to be able to trust their medicines. That is what the MEB is working on each and every day through the assessment and monitoring of the efficacy, risks and quality of medicines. I regard it as an honour to have the chance to contribute to this as chairman, together with extremely expert and passionate colleagues.”
Ton De Boer (1955) worked as an assistant physician for Internal Medicine and has a PhD in the field of clinical pharmacology. Following various posts in research and education (LUMC and later UU) he was appointed to the position of Professor in Pharmacotherapy and Director of Education of the Pharmacy School at Utrecht University in 2001. From 2007 until September 2015 he was Head of the Department of Pharmaceutical Sciences at Utrecht University. In addition to his post as chairman, he will continue to work part-time as professor at Utrecht University.
About the Medicines Evaluation Board
The Board consists, by law, of a maximum of 17 members, each of whom have a broad scientific, clinical and patient-oriented knowledge network in the Netherlands. The Board takes decisions about the admission of medicines to the Dutch market and is responsible for continuously monitoring all medicines on the Dutch market. The MEB is part of a European network of medicine regulatory authorities. The chairman and members of the Board are appointed by the Minister for Health, Welfare and Sport for a period of 4 years and can be reappointed no more than twice.